This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
BMYPositive Net Change PFEPositive Net Change CORTPositive Net Change TRDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
by Zacks Equity Research
Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
BIIBNegative Net Change BMRNNegative Net Change AGENPositive Net Change SAGEPositive Net Change
biotechnology biotechs
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
by Ahan Chakraborty
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pe-ratio pharmaceuticals
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
ANIPPositive Net Change VKTXPositive Net Change RAPTPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy BancFirst (BANF) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BANFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Redwood Trust (RWT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
RWTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
by Ekta Bagri
Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.
BIIBNegative Net Change BMRNNegative Net Change AGENPositive Net Change SAGEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
XERSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
by Zacks Equity Research
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
AMGNPositive Net Change AGENPositive Net Change ADVMPositive Net Change GPCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?
by Ekta Bagri
Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.
BMYPositive Net Change PFEPositive Net Change TSVTPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
SNYNegative Net Change AZNNegative Net Change BMYPositive Net Change ABBVPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.
GERNPositive Net Change AMGNPositive Net Change AGENPositive Net Change ADVMPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy
by Zacks Equity Research
Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy are part of the Zacks Screen of the Week article.
AMZNPositive Net Change THCPositive Net Change ATOPositive Net Change HALOPositive Net Change
biotechnology medical retail utilities
Bull of the Day: NVIDIA (NVDA)
by Kevin Cook
After Computex, I raised my price target to $200 because Wall Street still has no idea what's coming
NVDAPositive Net Change
aerospace alt-energy artificial-intelligence automation biotechnology cancer cloud-computing cybersecurity gene-therapy genomics oncology-screening semiconductor smart-health
Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System
by Zacks Equity Research
Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.
APositive Net Change INCYPositive Net Change ANETPositive Net Change PYPLPositive Net Change
biotechnology cell-therapy tech-stocks
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
by Zacks Equity Research
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
GSKPositive Net Change JNJPositive Net Change RAPTPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
AZNNegative Net Change BMYPositive Net Change CORTPositive Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
DocuSign (DOCU) Dips 12% in 6 Months: Is the Stock Worth Buying?
by Shuvra Shankar Dey
Given the recent decline in DocuSign (DOCU) shares, we evaluate the stock's current position to determine whether it presents a good investment opportunity at this time.
MSFTPositive Net Change CRMPositive Net Change DOCUPositive Net Change
biotechnology tech-stocks
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
by Ekta Bagri
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
VRTXPositive Net Change PRMENegative Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
by Zacks Equity Research
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
TEVAPositive Net Change ANIPPositive Net Change ADPTPositive Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
LXRXPositive Net Change SAVAPositive Net Change LXEONegative Net Change KYTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
by Zacks Equity Research
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
BAYRYNo Net Change ANIPPositive Net Change ADPTPositive Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
by Zacks Equity Research
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
ANIPPositive Net Change RARENegative Net Change ADPTPositive Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
JNJPositive Net Change BAYRYNo Net Change ORICPositive Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Amplify Energy (AMPY) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AMPYNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines